Healthcare
ImmuCell Corporation(ICCC)
Live Price
Offline$9.49
+1.06% today
1Y Change
+60.67%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $80.00M
- Revenue Growth
- +4.3%
- EPS Growth
- +53.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ImmuCell Corporation (ICCC) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $9.49 and up 60.7% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +4.3%, EPS growth of +53.8%, a dividend yield of 0.0%. What stands out right now is revenue +4.3%, EPS +53.8%, free cash flow +1236.0% with operating margin 6.0% and ROIC 4.1%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Stock Foundry combines ICCC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.3% vs +7.6% peer median
Operating Margin
Below sector median
+6.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 20, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +4.3% and EPS at +53.8%, with operating margin around 6.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 20, 2026 | โ | +1.3% | +0.2% | -3.9% |
2026 May 13, 2026 | โ | -1.2% | +18.2% | +16.5% |
2026 Mar 4, 2026 | -720.0% | -1.7% | +2.9% | -1.7% |
Benchmark Edge
ICCC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ICCC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ICCC Max Drawdown
-34.48%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ICCC and SPY.
Company Overview
ImmuCell Corporation
NASDAQ Capital Market
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
- Leadership
- F. Olivier Te Boekhorst
- IPO Date
- May 5, 1987
- Employees
- 69
- Street Address
- 56 Evergreen Drive
- Mailing
- Portland, ME, 04103
- Region
- Portland, ME, US
- Reporting Currency
- USD
- Investor Line
- 207 878 2770
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 18.1
- Price/Sales
- 2.8
- Price/Book
- 2.8
Growth
- Revenue
- +4.3%
- EPS
- +53.8%
- Free Cash Flow
- +1236.0%
Profitability
- Gross Margin
- 41.4%
- Operating Margin
- 6.0%
- Net Margin
- -3.8%
- ROE
- -3.6%
- ROIC
- 4.1%
Balance Sheet
- Debt/Equity
- 0.49
- Current Ratio
- 4.26
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.